acalabrutinibacuteadultsadvancedallogeneicamlanalysisasctautoleucelavdaxicabtagenebendamustinebestblinatumomabbonebortezomibcarecellchronicciloleucelclassiccombinationcomparedcontrolledcorticosteroidcyclophosphamidecytarabinedaratumumabdecitabinedexamethasonediagnoseddiffusediseasedonordonorsdosedoubleduplicationdurationfinalfirstfixedflt3followgilteritinibgraftguidedhaploidenticalhematopoietichighhlahodgkinhosthsctibrutinibiiiimmunochemotherapyinductioninfusioninternallabellargelenalidomideleukemialinelonglowlymphoblasticlymphocyticlymphomamaintenancemantlemarrowmatchedmethotrexatemrdmulticentermulticentremultiplemutationmycophenolatemyelodysplasticmyeloidmyelomanewlynivolumabolderopenoraloutcomespatientsphasephiladelphiaplacebopluspomalidomidepositivepostposttransplantposttransplantationpreventionprophylacticprophylaxisptcyrandomisedrandomizedreducedrefractoryrelapsedremissionresidualresultsriskrituximabruxolitinibstagestandardstemstudysubcutaneoussurvivalsyndrometacrolimustandemtermtherapytransplanttransplantationtreatedtreatmenttrialunrelateduntreatedvenetoclaxversuswithoutyearzanubrutinib